In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Telavancin is a dual action, bactericidal lipoglycopeptide. Its in vitro activity was compared with vancomycin and linezolid against 392 Gram-positive isolates from cancer patients. MIC90 values (μg ml(-1)) for telavancin, vancomycin and linezolid were determined for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), methicillin-susceptible (MS), methicillin-resistant (MR), coagulase-negative staphylococci (CoNS), viridans group streptococci (VGS), Streptococcus pneumoniae, Bacillus species, Corynebacterium species and Micrococcus species. Telavancin had potent activity against β-hemolytic streptococci and Staphylococcus lugdunensis. Whereas 100% of MRSA and 98% of MSSA had vancomycin MICs ⩾ 1.0 μg ml(-1) (minimum inhibitory concentrations (MICs) at which poor clinical responses have been reported), the highest telavancin MIC was 0.38 μg ml(-1). For CoNS, 95% of MS and 100% of MR isolates had vancomycin MICs ⩾ 1.0 μg ml(-1), whereas the highest telavancin MIC was 0.38 μg ml(-1). Furthermore, 48% of VGS had vancomycin MICs ⩾ 1.0 μg ml(-1), whereas the highest telavancin MIC was 0.064 μg ml(-1). A similar pattern was noticed for S. lugdunensis, Bacillus species, Corynebacterium species and β-hemolytic streptococci. These data suggest that telavancin and linezolid have potent activity against most Gram-positive organisms that cause infections in cancer patients. Consequently, they may be considered as alternatives to vancomycin, especially in institutions wherein a substantial proportion of infections are caused by organisms with vancomycin MICs ⩾ 1.0 μg ml(-1).
1] Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] University of Houston College of Pharmacy, Houston, TX, USA.
Kenneth
K
Rolston
University of Houston College of Pharmacy, Houston, TX, USA.
Weiqun
W
Wang
Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lior
0000000212300428
L
Nesher
1] Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] University of Houston College of Pharmacy, Houston, TX, USA.
Elizabeth
E
Coyle
Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samuel
S
Shelburne
1] Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] University of Houston College of Pharmacy, Houston, TX, USA.
Randall A
RA
Prince
D000081:Acetamides / Q000494:pharmacology*; D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000150:complications / Q000382:microbiology; D006801:Humans; D000069349:Linezolid; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology*; D023303:Oxazolidinones / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology*
D000081:Acetamides; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid; C487637:telavancin